ACRV vs. OGI, IVA, TELO, ATOS, LFCR, IXHL, ZVRA, GALT, GLSI, and TRVI Should you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Organigram (OGI), Inventiva (IVA), Telomir Pharmaceuticals (TELO), Atossa Therapeutics (ATOS), Lifecore Biomedical (LFCR), Incannex Healthcare (IXHL), Zevra Therapeutics (ZVRA), Galectin Therapeutics (GALT), Greenwich LifeSciences (GLSI), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical preparations" industry.
Acrivon Therapeutics (NASDAQ:ACRV ) and Organigram (NASDAQ:OGI ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, community ranking, valuation, earnings, analyst recommendations and media sentiment.
In the previous week, Acrivon Therapeutics had 1 more articles in the media than Organigram. MarketBeat recorded 16 mentions for Acrivon Therapeutics and 15 mentions for Organigram. Acrivon Therapeutics' average media sentiment score of 0.78 beat Organigram's score of 0.37 indicating that Acrivon Therapeutics is being referred to more favorably in the media.
71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Organigram shares are held by institutional investors. 7.3% of Acrivon Therapeutics shares are held by insiders. Comparatively, 0.1% of Organigram shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Acrivon Therapeutics has a net margin of 0.00% compared to Organigram's net margin of -188.38%. Organigram's return on equity of -40.19% beat Acrivon Therapeutics' return on equity.
Acrivon Therapeutics has higher earnings, but lower revenue than Organigram. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.
Acrivon Therapeutics currently has a consensus price target of $22.88, indicating a potential upside of 157.31%. Given Acrivon Therapeutics' higher probable upside, equities research analysts clearly believe Acrivon Therapeutics is more favorable than Organigram.
Organigram received 172 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 96.15% of users gave Acrivon Therapeutics an outperform vote while only 70.61% of users gave Organigram an outperform vote.
Acrivon Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.
Summary Acrivon Therapeutics beats Organigram on 10 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Acrivon Therapeutics Competitors List
Related Companies and Tools
